Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Feb 15.

Published in final edited form as: Clin Cancer Res. 2020 Oct 12;27(4):992–1002. doi: 10.1158/1078-0432.CCR-20-1690

Figure 3. — A. T790M (Detectable vs. Undetectable on Y axis) in circulating tumor DNA over time (3 time points, along X axis) and correlation with best overall response (color coded) and progression-free survival (ordered along Z axis by descending PFS). B. EGFR- Exon 19 deletion or Exon 21 L858R mutation in circulating tumor DNA similarly presented over time and correlation with best overall response and progression-free survival. Plasma samples were collected for assessment of circulating tumor DNA at baseline, during treatment (Cycle 4 Day 1 or Cycle 7 Day 1), and post progression (30-day follow-up). Genetic alterations were assessed by Guardant 360^® next-generation sequencing. Patients are color-coded according to best overall response. BOR, best overall response; CR, complete response; n, number of subjects in the specified category; NE, non-evaluable; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

Figure 3. — A. T790M (Detectable vs. Undetectable on Y axis) in circulating tumor DNA over time (3 time points, along X axis) and correlation with best overall response (color coded) and progression-free survival (ordered along Z axis by descending PFS). B. EGFR- Exon 19 deletion or Exon 21 L858R mutation in circulating tumor DNA similarly presented over time and correlation with best overall response and progression-free survival. Plasma samples were collected for assessment of circulating tumor DNA at baseline, during treatment (Cycle 4 Day 1 or Cycle 7 Day 1), and post progression (30-day follow-up). Genetic alterations were assessed by Guardant 360^® next-generation sequencing. Patients are color-coded according to best overall response. BOR, best overall response; CR, complete response; n, number of subjects in the specified category; NE, non-evaluable; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.